Skip to content
PaperFren

Concept

Pharmacogenetics and Drug Exposure

The same dose produces different blood levels and effects in different people, because of genes for drug-metabolising enzymes, body size, sex, co-medications and route of delivery. The evidence here comes from two African efavirenz studies, a Canadian case-control study of gabapentin with opioids, and a small asthma trial of an inhaled drug.

Students often assume dose equals exposure and that interactions come mainly from enzyme-inducing drugs. These studies show genotype can outweigh a famous interaction, that pharmacodynamic combinations can be lethal, and that delivery route can separate benefit from side effects.

Studies

4

Findings

4

4 supporting · 0 challenging · 1 qualifying citations

Open tensions

1

Currently

What we know

  1. Genes can change exposure more than tenfold at the same dose.
  2. Exposure links genotype to side effects, imperfectly.
  3. Additive respiratory depression is a real-world, dose-related hazard.
  4. Local delivery kept systemic exposure, and its side effects, low.

Largest unresolved question

Whether efavirenz levels explain CNS side effects differs between studies: the Ugandan prospective cohort linked higher levels to symptoms, while the Zimbabwean cross-sectional study of patients already on therapy found no difference. Timing matters, as Ugandan symptoms arose mostly in the first two weeks.

Common misconceptions

  • Rifampicin co-treatment is the main reason efavirenz levels vary in HIV-TB patients.

    Rifampicin lowered levels only in week one in Uganda and did not significantly affect clearance in Zimbabwe; CYP2B6 genotype had much larger effects.

  • Gabapentin is a safe add-on to opioids because it is not an opioid.

    Co-prescription carried 49% higher odds of opioid-related death in Ontario, in a dose-related pattern; this is observational but consistent with additive CNS depression.

Related